glp 1 agonist and alcohol use disorder GLP-1 Agonists for Disorder: UK Evidence Guidance Possible mechanisms by which GLP-1

Challenges and management of liver cirrhosis: Practical issues in the therapy of patients with cirrhosis due to NAFLD and NASH

Programs that offer subscription-based medication services often cost upwards of $300 per month, and these non-FDA approved compounded GLP-1 medications raise serious concerns due to variability in dosage, potential for harmful additives, and lack of rigorous safety and efficacy testing

analyzed commercial claims data (see Figure 2) and found that persistent GLP-1 users had $14K-$15K (about 14%) lower average annual total cost of care in the first one to two years of use compared with chronically obese patients who never tried GLP-1s

Nasopharyngitis, influenza, cystitis, and viral infection are also commonly reported with these drugs [48, 104-106, 110]